SOLANA BEACH, Calif. - ClearPoint Neuro, Inc. (NASDAQ:CLPT), a company specializing in precise navigation technology for the brain and spine, announced the pricing of its public offering at $6.50 per share.
The underwritten public offering consists of 2,307,694 shares, with an additional option granted to the underwriter to purchase up to 346,154 more shares at the public offering price, minus underwriting discounts and commissions.
The offering is scheduled to close on March 4, 2024, provided all customary closing conditions are met. ClearPoint Neuro plans to allocate the net proceeds from this offering towards general corporate activities, which may encompass research and development, potential acquisitions, or repayment of existing debt.
Lake Street Capital Markets, LLC is serving as the sole book-running manager for the offering. The securities are being offered pursuant to a shelf registration statement, which was declared effective by the Securities and Exchange Commission (SEC) on November 20, 2023.
ClearPoint Neuro's product portfolio includes the FDA-cleared and CE-marked ClearPoint Neuro Navigation System. The company collaborates with various healthcare, research, and pharmaceutical organizations globally, supporting numerous procedures with its clinical specialist team.
The information in this article is based on the press release statement from ClearPoint Neuro, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.